Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.
马萨诸塞州剑桥，2024 年 4 月 2 日（环球新闻专线）— 世代生物公司 纳斯达克股票代码：GBIO）是一家为罕见和流行病患者创新基因药物的生物技术公司，该公司宣布，总裁兼首席执行官杰夫·麦克唐纳医学博士将在美国东部时间2024年4月9日星期二下午 12:45 参加第23届Needham年度虚拟医疗会议的炉边谈话。
A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.
该演示文稿的网络直播将在公司网站的投资者专区播出 投资者 generationbio.com。活动结束后的30天内将在那里重播。
About Generation Bio
关于世代生物
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
Generation Bio正在创新非病毒基因药物，为数亿患有罕见和流行疾病的患者提供耐用和可重复剂量的治疗。该公司正在开发两个截然不同的互补平台：一种强大的、高选择性的细胞靶向脂质纳米颗粒（cTLnP）输送系统和一种新型免疫静默DNA（iQDNA）货物，该货物通过可扩展的无壳制造工艺生产，该工艺使用专有的无细胞快速酶促合成（RES）。借助这些平台，Generation Bio旨在开发下一波非病毒基因药物，以支持其使命，将基因医学的覆盖范围扩大到全球更多患有更多疾病的人。
For more information, please visit .
欲了解更多信息，请访问。
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
投资者和媒体联系人
玛伦·基拉基
生物世代
mkillackey@generationbio.com
857-371-4638